<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58826">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071134</url>
  </required_header>
  <id_info>
    <org_study_id>A4010</org_study_id>
    <nct_id>NCT02071134</nct_id>
  </id_info>
  <brief_title>Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry</brief_title>
  <official_title>Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to compile characteristics of world-wide outcomes for the
      use of Boston Scientific's commercially available Vercise DBS system in the treatment of
      Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this registry is to compile characteristics of world-wide outcomes for the
      use of Boston Scientific's commercially available Vercise DBS system in the treatment of
      Parkinson's disease.

      Subjects' improvement in disease symptoms and overall Quality of life will be assessed
      during the study following DBS and compared with baseline.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Improvement in patient's quality of life (QoL) during the study as compared with baseline</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in quality of life assessments during the study as compared with baseline</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in patient's motor symptoms as determined by UPDRS during the study as compared with baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in medication usage during the study as compared with baseline</measure>
    <time_frame>up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Impression of change scores during the study as compared with baseline</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Impression of change scores during the study as compared with baseline</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <description>Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation (DBS)</intervention_name>
    <description>Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.</description>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <other_name>Vercise DBS System</other_name>
    <other_name>Boston Scientific</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with symptoms of Parkinson's disease that are not adequately controlled with
        medication
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria established in locally applicable Vercise System Direction for Use

          -  At least 18 years old

        Exclusion Criteria:

          -  Meets any contraindication in the Vercise System locally applicable Directions for
             Use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nic Van Dyck</last_name>
    <phone>31-43-356-8328</phone>
    <email>VanDycKN@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Scientific International SA</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific Clinical Research</last_name>
      <email>BSNClinicaltrials@bsci.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep brain stimulation</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Vercise</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
